Paratek Pharmaceuticals Inc.
PRTK
Get informed when a big investor buys or sells
+ FollowMarket Cap$127.83M
Close$
$4.05
81.6% upside
Current Fair Value
81.6% upsideUndervalued by 81.6% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $127.83 Million |
|---|---|
| Enterprise Value | $379.70 Million |
| Dividend Yield | $31.97 (-) |
| Earnings per Share | $-1.17 |
| Beta | 1.7 |
| Outstanding Shares | 57,282,239 |
Return
| Return on Equity | 31.15% |
|---|---|
| Return on Assets | -43.03% |
| Return on Invested Capital | 78.04% |
Valuation & Multiples
| P/E Ratio | -1.91 |
|---|---|
| PEG | 10.96 |
| Price to Sales | 0.74 |
| Price to Book Ratio | -0.56 |
| Enterprise Value to Revenue | 2.19 |
| Enterprise Value to EBIT | -8.56 |
| Enterprise Value to Net Income | -7 |
| Total Debt to Enterprise | 0.78 |
| Debt to Equity | -1.46 |
Revenue Sources
No data
Insider Trades
Institutional Sentiment (Put/Call)
No data available for the latest quarter.
Institutional Ownership
No data available for the latest quarter.
ESG Score
No data
About Paratek Pharmaceuticals Inc.
CEO: Evan Loh